Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism
Open Access
- 9 October 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in The Pharmacogenomics Journal
- Vol. 8 (4), 268-277
- https://doi.org/10.1038/sj.tpj.6500482
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Human CYP2C8 Is Transcriptionally Regulated by the Nuclear Receptors Constitutive Androstane Receptor, Pregnane X Receptor, Glucocorticoid Receptor, and Hepatic Nuclear Factor 4αMolecular Pharmacology, 2005
- Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymesBiochemical and Biophysical Research Communications, 2005
- Transcriptional Regulation of the Human CYP2A6 GeneJournal of Pharmacology and Experimental Therapeutics, 2005
- A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatinJournal of Human Genetics, 2004
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004
- Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinideBritish Journal of Clinical Pharmacology, 2004
- CYTOCHROME P450 2C8 (CYP2C8)-MEDIATED HYDROXYLATION OF AN ENDOTHELIN ETA RECEPTOR ANTAGONIST IN HUMAN LIVER MICROSOMESPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2004
- The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjectsBritish Journal of Clinical Pharmacology, 2004
- The International HapMap ProjectNature, 2003
- Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5′-Upstream Regulatory RegionBiochemical and Biophysical Research Communications, 1999